Qu Biologics Enrolls First Patient in Phase 1/2 Clinical Trial of QBECO SSI for the Treatment of Crohn's Disease VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 11, 2013) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to "reboot" the...

Qu Biologics Welcomes Dr. Richard Fedorak and Dr. William Sandborn to Newly Formed IBD Advisory Team for Crohn's Disease Clinical Trial VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 30, 2013) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to "reboot" the body's...

Early Diagnosis and Public Awareness of Crohn's and Ulcerative Colitis Critical to Patient Care TORONTO, ONTARIO--(Marketwire - Nov. 23, 2011) - Imagine experiencing agonizing and debilitating pain that lasts for hours, months and even a year without a Doctor or Medical Practitioner...

Research Indicates Synthetic Compound NV-52 May Be Useful in Treatment of Inflammatory Bowel Disease NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - November 13, 2007) - An article published in a recent edition of the peer review journal Expert Opinion, Vol. 16, No. 8, reveals the compound...